Ambalal Sarabhai Enterprises Limited (AMBALALSA) fundamentals
Ambalal Sarabhai Enterprises Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as AMBALALSA (ISIN INE432A01017). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Ambalal Sarabhai Enterprises Limited does
Ambalal Sarabhai Enterprises Limited is an India-based company that is engaged in the business of manufacturing pharmaceuticals and electronics. The Company's segments include Pharmaceuticals and Electronics. Asence Inc., a wholly owned subsidiary of the Company, specializes in the supply of pharmaceutical preparations (finished dosage forms and active pharmaceutical ingredients) to the international markets. Its subsidiary, Sarabhai Chemicals (India) Private Limited, offers products in the oncology, infertility and Uro-gynaec areas. Its wholly owned subsidiary, Suvik Hitek Pvt. Ltd., is engaged in manufacturing pharmaceutical products and marketing generics and veterinary products in the domestic market. Its subsidiary, Systronics (India) Limited, is a manufacturer of analytical and test and measuring instruments, distributing its products across India. Its other subsidiaries include Synbiotics Limited, Asence Pharma Private Limited, and Sarabhai M Chemicals Limited, among others.
Valuation and market data
| Last close | ₹41.19 |
|---|---|
| Market capitalisation | ₹316 crore |
| Enterprise value | ₹334 crore |
| P/E (TTM) | 17.75 |
| Price to book | 2.00 |
| Price to sales (TTM) | 0.91 |
| Book value per share | ₹20.64 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Apr 20 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹20 crore | ₹10 crore | ₹11 crore | 1.43 |
| Mar 2025 | ₹19 crore | ₹8 crore | ₹8 crore | 1.08 |
| Mar 2024 | ₹12 crore | ₹1 crore | ₹3 crore | 0.34 |
| Mar 2023 | ₹14 crore | ₹4 crore | ₹4 crore | 0.54 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 31.4% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 68.6% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.